Cargando…
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated i...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945466/ https://www.ncbi.nlm.nih.gov/pubmed/35327530 http://dx.doi.org/10.3390/biomedicines10030727 |
_version_ | 1784673965432635392 |
---|---|
author | Guijarro, Luis G. Cano-Martínez, David Toledo-Lobo, M. Val Ruiz-Llorente, Lidia Chaparro, María Guerra, Iván Iborra, Marisa Cabriada, José Luis Bujanda, Luis Taxonera, Carlos García-Sánchez, Valle Marín-Jiménez, Ignacio Barreiro-de Acosta, Manuel Vera, Isabel Martín-Arranz, María Dolores Mesonero, Francisco Sempere, Laura Gomollón, Fernando Hinojosa, Joaquín Zoullas, Sofía Monserrat, Jorge Menor-Salvan, Cesar Alvarez-Mon, Melchor Gisbert, Javier P. Ortega, Miguel A. Hernández-Breijo, Borja |
author_facet | Guijarro, Luis G. Cano-Martínez, David Toledo-Lobo, M. Val Ruiz-Llorente, Lidia Chaparro, María Guerra, Iván Iborra, Marisa Cabriada, José Luis Bujanda, Luis Taxonera, Carlos García-Sánchez, Valle Marín-Jiménez, Ignacio Barreiro-de Acosta, Manuel Vera, Isabel Martín-Arranz, María Dolores Mesonero, Francisco Sempere, Laura Gomollón, Fernando Hinojosa, Joaquín Zoullas, Sofía Monserrat, Jorge Menor-Salvan, Cesar Alvarez-Mon, Melchor Gisbert, Javier P. Ortega, Miguel A. Hernández-Breijo, Borja |
author_sort | Guijarro, Luis G. |
collection | PubMed |
description | Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated in the PREDICROHN project, a prospective multicenter study of the Spanish Group of Inflammatory bowel disease (GETECCU). Results: This article demonstrates declines with respect to baseline levels of serum AIF-1 in Crohn’s disease (CD) patients after 14 weeks of treatment with anti-TNFs. Furthermore, in patients with active CD (HB ≥ 5), serum AIF-1 levels were significantly higher than those in patients without activity (HB ≤ 4). The study of serum AIF-1 in the same cohort, revealed an area under the ROC curve (AUC) value of AUC = 0.66 (p = 0.014), while for the CRP (C-reactive protein), (AUC) value of 0.69 (p = 0.0066), indicating a similar ability to classify CD patients by their severity. However, the combination of data on serum levels of AIF-1 and CRP improves the predictive ability of these analyses for classifying CD patients as active (HB ≥ 5) or inactive (HB ≤ 4). When we used the odds ratio (OR) formula, we observed that patients with CRP > 5 mg/L or AIF-1 > 200 pg/mL or both conditions were 13 times more likely to show HB ≥ 5 (active CD) than were those with both markers below these thresholds. Conclusion: The development of an algorithm that includes serum levels of AIF-1 and CRP could be useful for assessing Crohn’s disease severity. |
format | Online Article Text |
id | pubmed-8945466 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89454662022-03-25 Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity Guijarro, Luis G. Cano-Martínez, David Toledo-Lobo, M. Val Ruiz-Llorente, Lidia Chaparro, María Guerra, Iván Iborra, Marisa Cabriada, José Luis Bujanda, Luis Taxonera, Carlos García-Sánchez, Valle Marín-Jiménez, Ignacio Barreiro-de Acosta, Manuel Vera, Isabel Martín-Arranz, María Dolores Mesonero, Francisco Sempere, Laura Gomollón, Fernando Hinojosa, Joaquín Zoullas, Sofía Monserrat, Jorge Menor-Salvan, Cesar Alvarez-Mon, Melchor Gisbert, Javier P. Ortega, Miguel A. Hernández-Breijo, Borja Biomedicines Article Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated in the PREDICROHN project, a prospective multicenter study of the Spanish Group of Inflammatory bowel disease (GETECCU). Results: This article demonstrates declines with respect to baseline levels of serum AIF-1 in Crohn’s disease (CD) patients after 14 weeks of treatment with anti-TNFs. Furthermore, in patients with active CD (HB ≥ 5), serum AIF-1 levels were significantly higher than those in patients without activity (HB ≤ 4). The study of serum AIF-1 in the same cohort, revealed an area under the ROC curve (AUC) value of AUC = 0.66 (p = 0.014), while for the CRP (C-reactive protein), (AUC) value of 0.69 (p = 0.0066), indicating a similar ability to classify CD patients by their severity. However, the combination of data on serum levels of AIF-1 and CRP improves the predictive ability of these analyses for classifying CD patients as active (HB ≥ 5) or inactive (HB ≤ 4). When we used the odds ratio (OR) formula, we observed that patients with CRP > 5 mg/L or AIF-1 > 200 pg/mL or both conditions were 13 times more likely to show HB ≥ 5 (active CD) than were those with both markers below these thresholds. Conclusion: The development of an algorithm that includes serum levels of AIF-1 and CRP could be useful for assessing Crohn’s disease severity. MDPI 2022-03-21 /pmc/articles/PMC8945466/ /pubmed/35327530 http://dx.doi.org/10.3390/biomedicines10030727 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Guijarro, Luis G. Cano-Martínez, David Toledo-Lobo, M. Val Ruiz-Llorente, Lidia Chaparro, María Guerra, Iván Iborra, Marisa Cabriada, José Luis Bujanda, Luis Taxonera, Carlos García-Sánchez, Valle Marín-Jiménez, Ignacio Barreiro-de Acosta, Manuel Vera, Isabel Martín-Arranz, María Dolores Mesonero, Francisco Sempere, Laura Gomollón, Fernando Hinojosa, Joaquín Zoullas, Sofía Monserrat, Jorge Menor-Salvan, Cesar Alvarez-Mon, Melchor Gisbert, Javier P. Ortega, Miguel A. Hernández-Breijo, Borja Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity |
title | Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity |
title_full | Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity |
title_fullStr | Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity |
title_full_unstemmed | Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity |
title_short | Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity |
title_sort | evaluation of aif-1 (allograft inflammatory factor-1) as a biomarker of crohn’s disease severity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945466/ https://www.ncbi.nlm.nih.gov/pubmed/35327530 http://dx.doi.org/10.3390/biomedicines10030727 |
work_keys_str_mv | AT guijarroluisg evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT canomartinezdavid evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT toledolobomval evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT ruizllorentelidia evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT chaparromaria evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT guerraivan evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT iborramarisa evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT cabriadajoseluis evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT bujandaluis evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT taxoneracarlos evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT garciasanchezvalle evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT marinjimenezignacio evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT barreirodeacostamanuel evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT veraisabel evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT martinarranzmariadolores evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT mesonerofrancisco evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT semperelaura evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT gomollonfernando evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT hinojosajoaquin evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT zoullassofia evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT monserratjorge evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT menorsalvancesar evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT alvarezmonmelchor evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT gisbertjavierp evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT ortegamiguela evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity AT hernandezbreijoborja evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity |